[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fe3-REmDZYsrDJyOlj2Dkx7i930fHyK_oboUUQK0KBWo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":82,"rows":89},"Neurocrine Biosciences",[4],86,false,19,22,10195,6,2,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Schizophrenia",14,{"name":18,"count":19},"Tardive Dyskinesia",11,{"name":21,"count":22},"Major Depressive Disorder",10,{"name":24,"count":25},"Tourette Syndrome",8,{"name":27,"count":28},"Healthy Volunteers",7,{"name":30,"count":31},"Congenital Adrenal Hyperplasia",5,{"name":33,"count":34},"Parkinson's Disease",4,{"name":36,"count":37},"Chorea, Huntington",3,[39,44,48,53,57,61,66,71,74,77],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04806451","Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)","2023-03-10","Crinecerfont",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT04490915","Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia","2023-07-19",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04400331","Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease","2026-03","Valbenazine",{"nctId":54,"briefTitle":55,"date":56,"intervention":52},"NCT06312189","Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada","2026-04",{"nctId":58,"briefTitle":59,"date":60,"intervention":52},"NCT07105111","A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor","2027-01",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07365462","Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia","2027-02","NBI-1065890",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06963021","NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","2027-07","NBI-1065845",{"nctId":72,"briefTitle":73,"date":69,"intervention":70},"NCT06786624","Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",{"nctId":75,"briefTitle":76,"date":69,"intervention":70},"NCT06911112","NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07288333","Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia","2027-08","NBI-1117570",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,245,304,374,427,447,468,573,598,624,642,720,772,816,861,883,920,956,974,998,1022,1048,1073,1112,1149,1172,1197,1215,1233,1251,1269,1293,1311,1333,1358,1376,1400,1418,1436,1458,1485,1503,1521,1546,1564,1582],{"intervention":52,"totalTrials":91,"cells":92},15,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":139,"PHASE4":202,"NA":243},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[100,110,120,130],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT02879578","Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome","COMPLETED",[85],"2017-11-01","2016-07-25",155,[24],[52],{"nctId":111,"briefTitle":112,"status":103,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT03325010","Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",[85],"2018-11-01","2018-11-16","2017-10-05",127,[24],[52],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT03530293","Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome","TERMINATED",[85],"2019-07-16","2018-04-17",81,[24],[52],{"nctId":131,"briefTitle":132,"status":103,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT03444038","Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",[85],"2019-07-12","2018-02-08",85,[24],[52],{"trials":140,"activeCount":12,"soonestReadout":51},[141,148,159,167,177,186,196],{"nctId":49,"briefTitle":50,"status":142,"phases":143,"primaryCompletion":51,"completion":51,"start":144,"enrollment":145,"conditions":146,"interventions":147},"ACTIVE_NOT_RECRUITING",[86],"2020-09-18",154,[36],[52],{"nctId":149,"briefTitle":150,"status":103,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":6,"conditions":155,"interventions":158},"NCT05206513","Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy",[86],"2025-10-16","2026-03-31","2022-04-15",[156,157],"Dyskinesia","Cerebral Palsy",[52],{"nctId":160,"briefTitle":161,"status":123,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":25,"conditions":165,"interventions":166},"NCT05654870","Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia",[86],"2023-11-08","2023-01-05",[15],[52],{"nctId":168,"briefTitle":169,"status":103,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT04102579","Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease",[86],"2021-10-15","2021-10-26","2019-11-13",128,[36],[52],{"nctId":178,"briefTitle":179,"status":103,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT02736955","Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia",[86],"2017-06-30","2016-06-13",161,[18],[52],{"nctId":187,"briefTitle":188,"status":103,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":195},"NCT05110157","Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia",[86],"2025-02-04","2025-02-18","2021-11-29",442,[15],[52],{"nctId":54,"briefTitle":55,"status":197,"phases":198,"primaryCompletion":56,"completion":56,"start":199,"enrollment":28,"conditions":200,"interventions":201},"ENROLLING_BY_INVITATION",[86],"2024-04-24",[36],[52],{"trials":203,"activeCount":242,"soonestReadout":60},[204,213,223,233],{"nctId":58,"briefTitle":59,"status":205,"phases":206,"primaryCompletion":60,"completion":60,"start":207,"enrollment":208,"conditions":209,"interventions":212},"RECRUITING",[87],"2025-08-29",50,[15,210,211,21,18],"Schizoaffective Disorder","Bipolar Disorder",[52],{"nctId":214,"briefTitle":215,"status":103,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT03698331","The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine",[87],"2019-04-03","2018-09-14",89,[221],"Tardive Dyskinesia (TD)",[52],{"nctId":224,"briefTitle":225,"status":103,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":232},"NCT03891862","Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia",[87],"2019-12-23","2020-01-30","2019-03-18",135,[221],[52],{"nctId":234,"briefTitle":235,"status":103,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT05859698","Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia",[87],"2024-12-27","2023-05-09",59,[15,210,211,21,18],[52],1,{"trials":244,"activeCount":95},[],{"intervention":70,"totalTrials":11,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":263,"PHASE4":300,"NA":302},{"trials":248,"activeCount":95},[],{"trials":250,"activeCount":95},[],{"trials":252,"activeCount":95},[253],{"nctId":254,"briefTitle":255,"status":103,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT05203341","Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)",[85],"2024-01-10","2024-02-21","2022-02-21",183,[21],[70],{"trials":264,"activeCount":31,"soonestReadout":69},[265,275,281,290,295],{"nctId":266,"briefTitle":267,"status":205,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":274},"NCT06966401","Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",[86],"2029-05","2030-05","2025-04-16",850,[21],[70],{"nctId":67,"briefTitle":68,"status":205,"phases":276,"primaryCompletion":69,"completion":69,"start":277,"enrollment":278,"conditions":279,"interventions":280},[86],"2025-05-30",200,[21],[70],{"nctId":282,"briefTitle":283,"status":205,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":289},"NCT07196501","A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",[86],"2028-07","2025-08-18",550,[21],[70],{"nctId":72,"briefTitle":73,"status":205,"phases":291,"primaryCompletion":69,"completion":69,"start":292,"enrollment":278,"conditions":293,"interventions":294},[86],"2025-01-22",[21],[70],{"nctId":75,"briefTitle":76,"status":205,"phases":296,"primaryCompletion":69,"completion":69,"start":297,"enrollment":278,"conditions":298,"interventions":299},[86],"2025-03-31",[21],[70],{"trials":301,"activeCount":95},[],{"trials":303,"activeCount":95},[],{"intervention":305,"totalTrials":11,"cells":306},"NBI-1117568",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":333,"PHASE4":370,"NA":372},{"trials":308,"activeCount":95},[],{"trials":310,"activeCount":95},[],{"trials":312,"activeCount":242,"soonestReadout":326},[313,322],{"nctId":314,"briefTitle":315,"status":103,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT05545111","Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia",[85],"2024-07-10","2022-10-04",210,[15],[305],{"nctId":323,"briefTitle":324,"status":205,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":332},"NCT07288320","An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania",[85],"2028-02","2025-12-24",150,[330,331],"Bipolar I Disorder","Mania",[305],{"trials":334,"activeCount":34,"soonestReadout":366},[335,344,353,362],{"nctId":336,"briefTitle":337,"status":205,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT07227818","Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia",[86],"2029-07","2025-12-16",560,[15],[305],{"nctId":345,"briefTitle":346,"status":205,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT07114874","NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia",[86],"2031-12","2025-07-11",600,[15],[305],{"nctId":354,"briefTitle":355,"status":205,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT07105098","NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia",[86],"2027-11","2025-08-11",284,[15],[305],{"nctId":363,"briefTitle":364,"status":205,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":359,"conditions":368,"interventions":369},"NCT06963034","NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia",[86],"2027-10","2025-05-08",[15],[305],{"trials":371,"activeCount":95},[],{"trials":373,"activeCount":95},[],{"intervention":43,"totalTrials":31,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":409,"PHASE4":423,"NA":425},{"trials":377,"activeCount":95},[],{"trials":379,"activeCount":95},[],{"trials":381,"activeCount":12,"soonestReadout":387},[382,391,400],{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":387,"start":56,"enrollment":388,"conditions":389,"interventions":390},"NCT07536269","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old","NOT_YET_RECRUITING",[85],"2028-03",20,[30],[43],{"nctId":392,"briefTitle":393,"status":103,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":25,"conditions":397,"interventions":399},"NCT04045145","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia",[85],"2021-07-02","2019-12-12",[398],"CAH - Congenital Adrenal Hyperplasia",[43],{"nctId":401,"briefTitle":402,"status":205,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":11,"conditions":407,"interventions":408},"NCT07187375","Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old",[85],"2029-09-06","2029-10-04","2025-09-30",[30],[43],{"trials":410,"activeCount":12,"soonestReadout":42},[411,417],{"nctId":45,"briefTitle":46,"status":142,"phases":412,"primaryCompletion":47,"completion":80,"start":413,"enrollment":414,"conditions":415,"interventions":416},[86],"2020-12-16",182,[30],[43],{"nctId":40,"briefTitle":41,"status":142,"phases":418,"primaryCompletion":42,"completion":80,"start":419,"enrollment":420,"conditions":421,"interventions":422},[86],"2021-06-25",103,[30],[43],{"trials":424,"activeCount":95},[],{"trials":426,"activeCount":95},[],{"intervention":81,"totalTrials":242,"cells":428},{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":95},[],{"trials":434,"activeCount":242,"soonestReadout":80},[435],{"nctId":78,"briefTitle":79,"status":205,"phases":436,"primaryCompletion":80,"completion":80,"start":437,"enrollment":438,"conditions":439,"interventions":440},[85],"2026-02-16",120,[15],[81],{"trials":442,"activeCount":95},[],{"trials":444,"activeCount":95},[],{"trials":446,"activeCount":95},[],{"intervention":65,"totalTrials":242,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":450,"activeCount":95},[],{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":242,"soonestReadout":64},[455],{"nctId":62,"briefTitle":63,"status":205,"phases":456,"primaryCompletion":64,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},[85],"2027-03","2026-02-06",100,[18],[65],{"trials":463,"activeCount":95},[],{"trials":465,"activeCount":95},[],{"trials":467,"activeCount":95},[],{"intervention":469,"totalTrials":22,"cells":470},"NBI-98854",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":485,"PHASE3":548,"PHASE4":569,"NA":571},{"trials":472,"activeCount":95},[],{"trials":474,"activeCount":95},[475],{"nctId":476,"briefTitle":477,"status":103,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT02256475","Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome",[84],"2015-11","2015-12","2014-09",36,[24],[469],{"trials":486,"activeCount":95},[487,495,503,513,522,531,539],{"nctId":488,"briefTitle":489,"status":103,"phases":490,"primaryCompletion":491,"completion":491,"start":479,"enrollment":492,"conditions":493,"interventions":494},"NCT02581865","Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome",[85],"2016-12",124,[24],[469],{"nctId":496,"briefTitle":497,"status":103,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":22,"conditions":501,"interventions":502},"NCT01267188","Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia",[85],"2011-03","2011-01",[18],[469],{"nctId":504,"briefTitle":505,"status":103,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT01688037","NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)",[85],"2013-09","2013-10","2012-09",109,[18],[469,469],{"nctId":514,"briefTitle":515,"status":103,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":521},"NCT01733121","NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia",[85],"2013-12","2012-12",102,[18],[469,469],{"nctId":523,"briefTitle":524,"status":103,"phases":525,"primaryCompletion":526,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":530},"NCT02679079","Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome",[85],"2017-04-14","2016-03-23",98,[24],[469],{"nctId":532,"briefTitle":533,"status":123,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":11,"conditions":537,"interventions":538},"NCT03732534","Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome",[85],"2019-02-18","2018-10-17",[24],[469],{"nctId":540,"briefTitle":541,"status":103,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT01393600","NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder",[85],"2012-02","2011-08",37,[18],[469,469],{"trials":549,"activeCount":95},[550,559],{"nctId":551,"briefTitle":552,"status":103,"phases":553,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":558},"NCT02405091","Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia",[86],"2017-03","2015-03",167,[18],[469],{"nctId":560,"briefTitle":561,"status":103,"phases":562,"primaryCompletion":563,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":568},"NCT02274558","A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia",[86],"2015-09","2016-07","2014-10",234,[18],[469],{"trials":570,"activeCount":95},[],{"trials":572,"activeCount":95},[],{"intervention":574,"totalTrials":242,"cells":575},"NBI-34060",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":594,"NA":596},{"trials":577,"activeCount":95},[],{"trials":579,"activeCount":95},[],{"trials":581,"activeCount":95},[],{"trials":583,"activeCount":95},[584],{"nctId":585,"briefTitle":586,"status":587,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":95,"conditions":591,"interventions":593},"NCT00525941","An Exploratory Study of NBI-34060 Capsules and Next Day Functioning","WITHDRAWN",[86],"2008-01","2007-09",[592],"Insomnia",[574],{"trials":595,"activeCount":95},[],{"trials":597,"activeCount":95},[],{"intervention":599,"totalTrials":242,"cells":600},"Indiplon",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":620,"NA":622},{"trials":602,"activeCount":95},[],{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"trials":608,"activeCount":95},[609],{"nctId":610,"briefTitle":611,"status":123,"phases":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT00232167","Study Of Indiplon\u002FPlacebo With Sertraline In Insomnia Co-Existing With Depression",[86],"2006-04","2005-11",380,[592,617],"Depression",[599,619],"Sertraline",{"trials":621,"activeCount":95},[],{"trials":623,"activeCount":95},[],{"intervention":619,"totalTrials":242,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":638,"NA":640},{"trials":627,"activeCount":95},[],{"trials":629,"activeCount":95},[],{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":95},[634],{"nctId":610,"briefTitle":611,"status":123,"phases":635,"completion":613,"start":614,"enrollment":615,"conditions":636,"interventions":637},[86],[592,617],[599,619],{"trials":639,"activeCount":95},[],{"trials":641,"activeCount":95},[],{"intervention":643,"totalTrials":11,"cells":644},"TAK-831",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":702,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":646,"activeCount":95},[],{"trials":648,"activeCount":95},[649,660,670,680,689],{"nctId":650,"briefTitle":651,"status":103,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":11,"conditions":655,"interventions":656},"NCT04234672","A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants",[84],"2020-04-04","2020-02-17",[27],[657,658,659],"TAK-831 Oral","[14C]TAK-831 IV","[14C]TAK-831 Oral Suspension",{"nctId":661,"briefTitle":662,"status":103,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":388,"conditions":666,"interventions":668},"NCT02716987","Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration",[84],"2016-08-30","2016-03-21",[667],"Healthy",[643,669],"[18F]PGM299",{"nctId":671,"briefTitle":672,"status":103,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT03687684","Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects",[84],"2019-06-09","2019-06-19","2018-10-09",40,[27],[643],{"nctId":681,"briefTitle":682,"status":103,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":91,"conditions":687,"interventions":688},"NCT03101293","A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation",[84],"2017-05-19","2017-05-26","2017-04-04",[27],[643],{"nctId":690,"briefTitle":691,"status":123,"phases":692,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":699},"NCT02566759","A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants",[84],"2016-06-09","2016-07-12","2015-09-23",110,[698],"Schizophrenia, Cerebellar Ataxia",[700,701,643],"TAK-831 Oral Suspension","TAK-831 Placebo",{"trials":703,"activeCount":95},[704],{"nctId":705,"briefTitle":706,"status":103,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":713},"NCT03214588","Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia",[85],"2018-12-27","2017-11-08",67,[712],"Friedreich Ataxia",[643,701],{"trials":715,"activeCount":95},[],{"trials":717,"activeCount":95},[],{"trials":719,"activeCount":95},[],{"intervention":721,"totalTrials":34,"cells":722},"NBI-921352",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[],{"trials":728,"activeCount":95},[729,740,749,758],{"nctId":730,"briefTitle":731,"status":123,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":739},"NCT05493293","Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures",[85],"2024-03-11","2022-11-09",82,[737,738],"Focal Onset Seizure","Focal Onset Epilepsy",[721],{"nctId":741,"briefTitle":742,"status":123,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":25,"conditions":746,"interventions":748},"NCT04873869","Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",[85],"2023-03-17","2022-01-31",[747],"SCN8A Developmental and Epileptic Encephalopathy Syndrome",[721],{"nctId":750,"briefTitle":751,"status":103,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT05159908","A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures",[85],"2023-08-21","2021-11-08",101,[737,738],[721],{"nctId":759,"briefTitle":760,"status":123,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":25,"conditions":764,"interventions":765},"NCT05226780","Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE",[85],"2025-11-12","2022-07-12",[747],[721],{"trials":767,"activeCount":95},[],{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":95},[],{"intervention":773,"totalTrials":37,"cells":774},"Luvadaxistat",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":776,"activeCount":95},[],{"trials":778,"activeCount":95},[],{"trials":780,"activeCount":95},[781,791,801],{"nctId":782,"briefTitle":783,"status":103,"phases":784,"primaryCompletion":785,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":790},"NCT03382639","A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia",[85],"2020-12-29","2021-01-12","2018-01-04",256,[15],[773],{"nctId":792,"briefTitle":793,"status":123,"phases":794,"primaryCompletion":795,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":800},"NCT05182476","Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia",[85],"2024-06-28","2024-10-14","2021-12-07",216,[15],[773],{"nctId":802,"briefTitle":803,"status":103,"phases":804,"primaryCompletion":805,"completion":805,"start":806,"enrollment":807,"conditions":808,"interventions":809},"NCT03359785","A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia",[85],"2020-12-21","2018-01-10",31,[15],[773],{"trials":811,"activeCount":95},[],{"trials":813,"activeCount":95},[],{"trials":815,"activeCount":95},[],{"intervention":817,"totalTrials":37,"cells":818},"NBI-827104",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":820,"activeCount":95},[],{"trials":822,"activeCount":95},[],{"trials":824,"activeCount":95},[825,837,845],{"nctId":826,"briefTitle":827,"status":103,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":836},"NCT04625101","Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep",[85],"2022-08-08","2022-10-11","2021-04-26",24,[834,835],"Epileptic Encephalopathy","Continuous Spike and Wave During Sleep",[817],{"nctId":838,"briefTitle":839,"status":123,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":8,"conditions":843,"interventions":844},"NCT05301894","Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep",[85],"2025-01-27","2022-06-07",[834,835],[817],{"nctId":846,"briefTitle":847,"status":103,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":807,"conditions":852,"interventions":854},"NCT04880616","Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor",[85],"2022-05-25","2022-06-08","2021-04-20",[853],"Essential Tremor",[817],{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[],{"trials":860,"activeCount":95},[],{"intervention":701,"totalTrials":12,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":871,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":864,"activeCount":95},[],{"trials":866,"activeCount":95},[867],{"nctId":690,"briefTitle":691,"status":123,"phases":868,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":869,"interventions":870},[84],[698],[700,701,643],{"trials":872,"activeCount":95},[873],{"nctId":705,"briefTitle":706,"status":103,"phases":874,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":875,"interventions":876},[85],[712],[643,701],{"trials":878,"activeCount":95},[],{"trials":880,"activeCount":95},[],{"trials":882,"activeCount":95},[],{"intervention":884,"totalTrials":12,"cells":885},"TAK-041",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":900,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":887,"activeCount":95},[],{"trials":889,"activeCount":95},[890],{"nctId":891,"briefTitle":892,"status":103,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":898},"NCT02748694","Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",[84],"2019-09-22","2016-05-09",114,[27,15],[884,899],"TAK-041 Placebo",{"trials":901,"activeCount":95},[902],{"nctId":903,"briefTitle":904,"status":103,"phases":905,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT03319953","A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia",[85],"2019-09-11","2019-11-06","2017-12-21",23,[911],"Stable Schizophrenia",[884,913],"Second Generation Antipsychotics",{"trials":915,"activeCount":95},[],{"trials":917,"activeCount":95},[],{"trials":919,"activeCount":95},[],{"intervention":921,"totalTrials":12,"cells":922},"interleukin-4 PE38KDEL cytotoxin",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":939,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":924,"activeCount":95},[],{"trials":926,"activeCount":95},[927],{"nctId":928,"briefTitle":929,"status":103,"phases":930,"primaryCompletion":931,"completion":932,"start":933,"conditions":934,"interventions":938},"NCT00039052","Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer",[84],"2003-05","2008-07","2002-01",[935,936,937],"Breast Cancer","Kidney Cancer","Lung Cancer",[921],{"trials":940,"activeCount":95},[941],{"nctId":942,"briefTitle":943,"status":103,"phases":944,"primaryCompletion":945,"completion":932,"start":946,"conditions":947,"interventions":949},"NCT00014677","NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme",[85],"2002-09","2001-03",[948],"Brain and Central Nervous System Tumors",[921],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"trials":955,"activeCount":95},[],{"intervention":913,"totalTrials":242,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":959,"activeCount":95},[],{"trials":961,"activeCount":95},[],{"trials":963,"activeCount":95},[964],{"nctId":903,"briefTitle":904,"status":103,"phases":965,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":966,"interventions":967},[85],[911],[884,913],{"trials":969,"activeCount":95},[],{"trials":971,"activeCount":95},[],{"trials":973,"activeCount":95},[],{"intervention":975,"totalTrials":242,"cells":976},"NBI-5788",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":978,"activeCount":95},[],{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[983],{"nctId":984,"briefTitle":985,"status":103,"phases":986,"completion":987,"start":988,"enrollment":328,"conditions":989,"interventions":991},"NCT00079495","Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)",[85],"2005-04","2003-07",[990],"Multiple Sclerosis",[975],{"trials":993,"activeCount":95},[],{"trials":995,"activeCount":95},[],{"trials":997,"activeCount":95},[],{"intervention":999,"totalTrials":242,"cells":1000},"NBI-74788",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1002,"activeCount":95},[],{"trials":1004,"activeCount":95},[],{"trials":1006,"activeCount":95},[1007],{"nctId":1008,"briefTitle":1009,"status":103,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT03525886","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia",[85],"2020-04-07","2018-04-10",18,[398],[999],{"trials":1017,"activeCount":95},[],{"trials":1019,"activeCount":95},[],{"trials":1021,"activeCount":95},[],{"intervention":1023,"totalTrials":242,"cells":1024},"NBI-1065846",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1026,"activeCount":95},[],{"trials":1028,"activeCount":95},[],{"trials":1030,"activeCount":95},[1031],{"nctId":1032,"briefTitle":1033,"status":103,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT05165394","Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD",[85],"2023-07-07","2023-09-13","2021-11-30",93,[1040,21],"Anhedonia",[1023],{"trials":1043,"activeCount":95},[],{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[],{"intervention":1049,"totalTrials":242,"cells":1050},"NBI-1070770",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1052,"activeCount":95},[],{"trials":1054,"activeCount":95},[],{"trials":1056,"activeCount":95},[1057],{"nctId":1058,"briefTitle":1059,"status":103,"phases":1060,"primaryCompletion":1061,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1066},"NCT06267846","A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder",[85],"2025-07-25","2025-09-11","2024-03-20",73,[21],[1049],{"trials":1068,"activeCount":95},[],{"trials":1070,"activeCount":95},[],{"trials":1072,"activeCount":95},[],{"intervention":1074,"totalTrials":12,"cells":1075},"VY-AADC01",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1104,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1077,"activeCount":95},[],{"trials":1079,"activeCount":95},[1080,1087],{"nctId":1081,"briefTitle":1082,"status":103,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":508,"enrollment":91,"conditions":1085,"interventions":1086},"NCT01973543","Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease",[84],"2020-01-24",[33],[1074],{"nctId":1088,"briefTitle":1089,"status":103,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1103},"NCT03065192","Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease",[84],"2021-08-10","2017-05-11",16,[1095,33,1096,1097,1098,1099,1100,1101,1102],"Idiopathic Parkinson's Disease","Basal Ganglia Disease","Brain Diseases","Central Nervous System Diseases","Movement Disorders","Nervous System Diseases","Neurodegenerative Diseases","Parkinsonian Disorders",[1074],{"trials":1105,"activeCount":95},[],{"trials":1107,"activeCount":95},[],{"trials":1109,"activeCount":95},[],{"trials":1111,"activeCount":95},[],{"intervention":1113,"totalTrials":12,"cells":1114},"TAK-653",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1116,"activeCount":95},[],{"trials":1118,"activeCount":95},[1119,1129],{"nctId":1120,"briefTitle":1121,"status":103,"phases":1122,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":832,"conditions":1126,"interventions":1127},"NCT03792672","A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)",[84],"2019-05-15","2019-06-18","2019-02-11",[27],[1113,1128],"Ketamine",{"nctId":1130,"briefTitle":1131,"status":103,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT02561156","TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants",[84],"2017-09-11","2017-09-23","2015-08-26",88,[1138],"Depressive Disorder",[1140,1113],"TAK-653 Placebo",{"trials":1142,"activeCount":95},[],{"trials":1144,"activeCount":95},[],{"trials":1146,"activeCount":95},[],{"trials":1148,"activeCount":95},[],{"intervention":1150,"totalTrials":242,"cells":1151},"NBI-77860",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1153,"activeCount":95},[],{"trials":1155,"activeCount":95},[1156],{"nctId":1157,"briefTitle":1158,"status":587,"phases":1159,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":95,"conditions":1162,"interventions":1163},"NCT02349503","Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia",[84],"2015-10","2015-02",[30],[1150,1150,1150],{"trials":1165,"activeCount":95},[],{"trials":1167,"activeCount":95},[],{"trials":1169,"activeCount":95},[],{"trials":1171,"activeCount":95},[],{"intervention":1173,"totalTrials":242,"cells":1174},"NBI-6024",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1176,"activeCount":95},[],{"trials":1178,"activeCount":95},[1179],{"nctId":1180,"briefTitle":1181,"status":103,"phases":1182,"primaryCompletion":613,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1188},"NCT00873561","A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus",[84],"2006-07","2001-12",188,[1187],"Type 1 Diabetes Mellitus",[1173],{"trials":1190,"activeCount":95},[],{"trials":1192,"activeCount":95},[],{"trials":1194,"activeCount":95},[],{"trials":1196,"activeCount":95},[],{"intervention":1128,"totalTrials":242,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1200,"activeCount":95},[],{"trials":1202,"activeCount":95},[1203],{"nctId":1120,"briefTitle":1121,"status":103,"phases":1204,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":832,"conditions":1205,"interventions":1206},[84],[27],[1113,1128],{"trials":1208,"activeCount":95},[],{"trials":1210,"activeCount":95},[],{"trials":1212,"activeCount":95},[],{"trials":1214,"activeCount":95},[],{"intervention":658,"totalTrials":242,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1218,"activeCount":95},[],{"trials":1220,"activeCount":95},[1221],{"nctId":650,"briefTitle":651,"status":103,"phases":1222,"primaryCompletion":653,"completion":653,"start":654,"enrollment":11,"conditions":1223,"interventions":1224},[84],[27],[657,658,659],{"trials":1226,"activeCount":95},[],{"trials":1228,"activeCount":95},[],{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[],{"intervention":659,"totalTrials":242,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1243,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1236,"activeCount":95},[],{"trials":1238,"activeCount":95},[1239],{"nctId":650,"briefTitle":651,"status":103,"phases":1240,"primaryCompletion":653,"completion":653,"start":654,"enrollment":11,"conditions":1241,"interventions":1242},[84],[27],[657,658,659],{"trials":1244,"activeCount":95},[],{"trials":1246,"activeCount":95},[],{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[],{"intervention":899,"totalTrials":242,"cells":1252},{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1261,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1254,"activeCount":95},[],{"trials":1256,"activeCount":95},[1257],{"nctId":891,"briefTitle":892,"status":103,"phases":1258,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1259,"interventions":1260},[84],[27,15],[884,899],{"trials":1262,"activeCount":95},[],{"trials":1264,"activeCount":95},[],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[],{"intervention":1270,"totalTrials":242,"cells":1271},"Carbidopa Levodopa",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1273,"activeCount":95},[],{"trials":1275,"activeCount":95},[1276],{"nctId":1277,"briefTitle":1278,"status":103,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":135,"enrollment":1093,"conditions":1281,"interventions":1283},"NCT03496870","A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.",[84],"2018-07-02",[1282],"Parkinson Disease",[1284,1270],"Opicapone",{"trials":1286,"activeCount":95},[],{"trials":1288,"activeCount":95},[],{"trials":1290,"activeCount":95},[],{"trials":1292,"activeCount":95},[],{"intervention":669,"totalTrials":242,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":95},[],{"trials":1298,"activeCount":95},[1299],{"nctId":661,"briefTitle":662,"status":103,"phases":1300,"primaryCompletion":664,"completion":664,"start":665,"enrollment":388,"conditions":1301,"interventions":1302},[84],[667],[643,669],{"trials":1304,"activeCount":95},[],{"trials":1306,"activeCount":95},[],{"trials":1308,"activeCount":95},[],{"trials":1310,"activeCount":95},[],{"intervention":1312,"totalTrials":242,"cells":1313},"VY-AADC02",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1331},{"trials":1315,"activeCount":95},[],{"trials":1317,"activeCount":95},[1318],{"nctId":1319,"briefTitle":1320,"status":103,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":536,"enrollment":16,"conditions":1323,"interventions":1324},"NCT03562494","VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)",[84],"2024-10-30",[33],[1312],{"trials":1326,"activeCount":95},[],{"trials":1328,"activeCount":95},[],{"trials":1330,"activeCount":95},[],{"trials":1332,"activeCount":95},[],{"intervention":1334,"totalTrials":242,"cells":1335},"NBI-98854 50 mg capsule once daily",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1337,"activeCount":95},[],{"trials":1339,"activeCount":95},[1340],{"nctId":1341,"briefTitle":1342,"status":103,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":832,"conditions":1346,"interventions":1348},"NCT01910480","Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects",[84],"2013-08","2013-07",[1347],"Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects",[1334,1349],"Ketoconazole 400 mg",{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[],{"trials":1357,"activeCount":95},[],{"intervention":1349,"totalTrials":242,"cells":1359},{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1361,"activeCount":95},[],{"trials":1363,"activeCount":95},[1364],{"nctId":1341,"briefTitle":1342,"status":103,"phases":1365,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":832,"conditions":1366,"interventions":1367},[84],[1347],[1334,1349],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[],{"trials":1373,"activeCount":95},[],{"trials":1375,"activeCount":95},[],{"intervention":1377,"totalTrials":242,"cells":1378},"TAK-831 Tablet T2",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1392,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1380,"activeCount":95},[],{"trials":1382,"activeCount":95},[1383],{"nctId":1384,"briefTitle":1385,"status":103,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":208,"conditions":1389,"interventions":1390},"NCT03224325","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants",[84],"2018-09-09","2017-07-21",[667],[1377,1391],"TAK-831 Suspension",{"trials":1393,"activeCount":95},[],{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[],{"intervention":1391,"totalTrials":242,"cells":1401},{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1403,"activeCount":95},[],{"trials":1405,"activeCount":95},[1406],{"nctId":1384,"briefTitle":1385,"status":103,"phases":1407,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":208,"conditions":1408,"interventions":1409},[84],[667],[1377,1391],{"trials":1411,"activeCount":95},[],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[],{"trials":1417,"activeCount":95},[],{"intervention":1140,"totalTrials":242,"cells":1419},{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1421,"activeCount":95},[],{"trials":1423,"activeCount":95},[1424],{"nctId":1130,"briefTitle":1131,"status":103,"phases":1425,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1136,"conditions":1426,"interventions":1427},[84],[1138],[1140,1113],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[],{"trials":1435,"activeCount":95},[],{"intervention":1437,"totalTrials":242,"cells":1438},"NBI-98854 50 mg",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1440,"activeCount":95},[],{"trials":1442,"activeCount":95},[1443],{"nctId":1444,"briefTitle":1445,"status":103,"phases":1446,"primaryCompletion":517,"completion":517,"start":1344,"enrollment":832,"conditions":1447,"interventions":1449},"NCT01916993","Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency",[84],[1448],"Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects",[1437],{"trials":1451,"activeCount":95},[],{"trials":1453,"activeCount":95},[],{"trials":1455,"activeCount":95},[],{"trials":1457,"activeCount":95},[],{"intervention":1459,"totalTrials":242,"cells":1460},"Amphetamine",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[1465],{"nctId":1466,"briefTitle":1467,"status":103,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT02959892","A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)",[84],"2017-05-30","2017-08-23","2016-12-05",12,[27],[1459,1475,1476],"TAK -041","[11C]",{"trials":1478,"activeCount":95},[],{"trials":1480,"activeCount":95},[],{"trials":1482,"activeCount":95},[],{"trials":1484,"activeCount":95},[],{"intervention":1475,"totalTrials":242,"cells":1486},{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[1491],{"nctId":1466,"briefTitle":1467,"status":103,"phases":1492,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1493,"interventions":1494},[84],[27],[1459,1475,1476],{"trials":1496,"activeCount":95},[],{"trials":1498,"activeCount":95},[],{"trials":1500,"activeCount":95},[],{"trials":1502,"activeCount":95},[],{"intervention":1476,"totalTrials":242,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1513,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":95},[],{"trials":1508,"activeCount":95},[1509],{"nctId":1466,"briefTitle":1467,"status":103,"phases":1510,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1511,"interventions":1512},[84],[27],[1459,1475,1476],{"trials":1514,"activeCount":95},[],{"trials":1516,"activeCount":95},[],{"trials":1518,"activeCount":95},[],{"trials":1520,"activeCount":95},[],{"intervention":1522,"totalTrials":242,"cells":1523},"TAK-831 T2",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1525,"activeCount":95},[],{"trials":1527,"activeCount":95},[1528],{"nctId":1529,"briefTitle":1530,"status":103,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1093,"conditions":1535,"interventions":1536},"NCT03706469","A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants",[84],"2018-12-11","2018-12-22","2018-10-18",[27],[1522,1537],"TAK-831 T3",{"trials":1539,"activeCount":95},[],{"trials":1541,"activeCount":95},[],{"trials":1543,"activeCount":95},[],{"trials":1545,"activeCount":95},[],{"intervention":1537,"totalTrials":242,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1556,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1549,"activeCount":95},[],{"trials":1551,"activeCount":95},[1552],{"nctId":1529,"briefTitle":1530,"status":103,"phases":1553,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1093,"conditions":1554,"interventions":1555},[84],[27],[1522,1537],{"trials":1557,"activeCount":95},[],{"trials":1559,"activeCount":95},[],{"trials":1561,"activeCount":95},[],{"trials":1563,"activeCount":95},[],{"intervention":700,"totalTrials":242,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1567,"activeCount":95},[],{"trials":1569,"activeCount":95},[1570],{"nctId":690,"briefTitle":691,"status":123,"phases":1571,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":1572,"interventions":1573},[84],[698],[700,701,643],{"trials":1575,"activeCount":95},[],{"trials":1577,"activeCount":95},[],{"trials":1579,"activeCount":95},[],{"trials":1581,"activeCount":95},[],{"intervention":1284,"totalTrials":12,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1592,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":95},[],{"trials":1587,"activeCount":95},[1588],{"nctId":1277,"briefTitle":1278,"status":103,"phases":1589,"primaryCompletion":1280,"completion":1280,"start":135,"enrollment":1093,"conditions":1590,"interventions":1591},[84],[1282],[1284,1270],{"trials":1593,"activeCount":95},[],{"trials":1595,"activeCount":95},[],{"trials":1597,"activeCount":95},[],{"trials":1599,"activeCount":95},[1600],{"nctId":1601,"briefTitle":1602,"status":103,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1608},"NCT04787965","Opicapone Treatment Initiation Open-Label Study",[],"2022-08-04","2021-03-01",239,[1282],[1284]]